Palvella Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Palvella Therapeutics, Inc. (PVLA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- Palvella Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.16M, a 259.73% increase year-over-year.
- Palvella Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.38M, a 208.59% increase year-over-year.
- Palvella Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.79M, a 799.50% increase year-over-year.
- Palvella Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.43M, a 560.37% increase year-over-year.
- Palvella Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.40M, a 671.20% increase from fiscal 2024.
- Palvella Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $830.00K, a 37.65% increase from fiscal 2023.
- Palvella Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $603.00K, a 86.30% decline from fiscal 2022.
- Palvella Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.40M, a 15.59% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5.16M 10-Q · filed 2026-08-04 | $8.53M derived: sum of 2 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $3.38M 10-Q · filed 2026-08-04 | |||||
| 2025-12-31 | $6.40M 10-K · filed 2026-03-31 | |||||
| 2025-09-30 | $1.79M 10-Q · filed 2025-11-12 | $3.22M derived: sum of 2 quarters · filed 2026-08-04 | $4.32M derived: sum of 3 quarters · filed 2026-08-04 | $3.92M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $1.43M 10-Q · filed 2026-08-04 | $2.53M derived: sum of 2 quarters · filed 2026-08-04 | $2.13M derived: sum of 3 quarters · filed 2026-08-04 | $2.33M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $1.09M 10-Q · filed 2026-08-04 | $701.00K derived: sum of 2 quarters · filed 2026-08-04 | $900.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.12M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2024-12-31 | -$393.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$194.00K derived: sum of 2 quarters · filed 2026-03-31 | $23.00K derived: sum of 3 quarters · filed 2026-03-31 | $830.00K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $199.00K 10-Q · filed 2025-11-12 | $330.00K 10-Q · filed 2024-11-13 | $416.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.22M 10-Q · filed 2024-11-13 | -$1.73M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $217.00K 10-Q · filed 2025-11-12 | $421.00K 10-Q · filed 2024-08-14 | $893.00K 10-Q · filed 2024-08-14 | -$1.93M derived: sum of 3 quarters · filed 2025-11-12 | -$966.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-03-31 | $146.00K 10-Q · filed 2025-11-12 | $472.00K 10-Q · filed 2024-05-15 | -$2.15M derived: sum of 2 quarters · filed 2025-11-12 | -$1.18M derived: sum of 3 quarters · filed 2025-11-12 | -$135.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2023-12-31 | -$2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.33M derived: sum of 2 quarters · filed 2025-03-31 | -$281.00K derived: sum of 3 quarters · filed 2025-03-31 | $603.00K 10-K · filed 2025-03-31 | $3.35M 10-K · filed 2024-03-29 | |
| 2023-09-30 | $966.00K 10-Q · filed 2024-11-13 | $2.01M derived: sum of 2 quarters · filed 2024-11-13 | $2.90M 10-Q · filed 2024-11-13 | $3.85M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $1.05M 10-Q · filed 2024-08-14 | $1.93M 10-Q · filed 2024-08-14 | $2.88M derived: sum of 3 quarters · filed 2024-08-14 | $3.85M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $884.00K 10-Q · filed 2024-05-15 | $1.83M derived: sum of 2 quarters · filed 2024-05-15 | $2.81M derived: sum of 3 quarters · filed 2024-05-15 | $4.11M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $949.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.92M derived: sum of 2 quarters · filed 2024-03-29 | $3.22M derived: sum of 3 quarters · filed 2024-03-29 | $4.40M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $974.00K 10-Q · filed 2023-11-14 | $2.27M derived: sum of 2 quarters · filed 2023-11-14 | $3.45M 10-Q · filed 2023-11-14 | $4.77M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $1.30M 10-Q · filed 2023-08-10 | $2.48M 10-Q · filed 2023-08-10 | $3.80M derived: sum of 3 quarters · filed 2023-08-10 | $5.17M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $1.18M 10-Q · filed 2023-05-11 | $2.50M derived: sum of 2 quarters · filed 2023-05-11 | $3.87M derived: sum of 3 quarters · filed 2023-05-11 | $5.19M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.69M derived: sum of 2 quarters · filed 2023-03-31 | $4.02M derived: sum of 3 quarters · filed 2023-03-31 | $5.21M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $1.37M 10-Q · filed 2022-11-04 | $2.70M derived: sum of 2 quarters · filed 2022-11-04 | $3.90M 10-Q · filed 2022-11-04 | $5.07M derived: sum of 4 quarters · filed 2022-11-04 | ||
| 2021-06-30 | $1.33M 10-Q · filed 2022-08-04 | $2.52M 10-Q · filed 2022-08-04 | $3.70M derived: sum of 3 quarters · filed 2022-08-04 | $5.09M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-11 | $2.37M derived: sum of 2 quarters · filed 2022-05-11 | $3.77M derived: sum of 3 quarters · filed 2022-05-11 | $5.01M derived: sum of 4 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $2.57M derived: sum of 2 quarters · filed 2022-03-02 | $3.81M derived: sum of 3 quarters · filed 2022-03-02 | $5.09M 10-K · filed 2022-03-02 | ||
| 2020-09-30 | $1.40M 10-Q · filed 2021-11-02 | $2.63M derived: sum of 2 quarters · filed 2021-11-02 | $3.92M 10-Q · filed 2021-11-02 | $5.03M derived: sum of 4 quarters · filed 2021-11-02 | ||
| 2020-06-30 | $1.24M 10-Q · filed 2021-08-05 | $2.52M 10-Q · filed 2021-08-05 | $3.63M derived: sum of 3 quarters · filed 2021-08-05 | $5.15M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $1.28M 10-Q · filed 2021-05-17 | $2.40M derived: sum of 2 quarters · filed 2021-05-17 | $3.92M derived: sum of 3 quarters · filed 2021-05-17 | $5.37M derived: sum of 4 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $2.63M derived: sum of 2 quarters · filed 2021-03-31 | $4.08M derived: sum of 3 quarters · filed 2021-03-31 | $5.37M 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $1.52M 10-Q · filed 2020-11-04 | $2.97M derived: sum of 2 quarters · filed 2020-11-04 | $4.26M 10-Q · filed 2020-11-04 | $5.54M derived: sum of 4 quarters · filed 2020-11-04 | ||
| 2019-06-30 | $1.45M 10-Q · filed 2020-08-10 | $2.74M 10-Q · filed 2020-08-10 | $4.02M derived: sum of 3 quarters · filed 2020-08-10 | $5.32M derived: sum of 4 quarters · filed 2020-08-10 | ||
| 2019-03-31 | $1.29M 10-Q · filed 2020-05-11 | $2.57M derived: sum of 2 quarters · filed 2020-05-11 | $3.87M derived: sum of 3 quarters · filed 2020-05-11 | $5.23M derived: sum of 4 quarters · filed 2020-05-11 | ||
| 2018-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $2.58M derived: sum of 2 quarters · filed 2020-03-13 | $3.94M derived: sum of 3 quarters · filed 2020-03-13 | $4.94M 10-K · filed 2020-03-13 | ||
| 2018-09-30 | $1.30M 10-Q · filed 2019-11-12 | $2.66M derived: sum of 2 quarters · filed 2019-11-12 | $3.67M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $1.36M 10-Q · filed 2019-08-09 | $2.36M 10-Q · filed 2019-08-09 | ||||
| 2018-03-31 | $1.00M 10-Q · filed 2019-05-10 | |||||
| 2017-12-31 | $3.05M 10-K · filed 2019-03-18 | |||||
| 2016-12-31 | $1.91M 10-K · filed 2018-03-15 | $1.91M 10-K · filed 2017-03-30 | ||||
| 2015-12-31 | $1.16M 10-K · filed 2017-03-30 | |||||
| 2014-12-31 | $571.38K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |